This document provides an overview of precision medicine. It defines precision medicine as an emerging approach to disease treatment and prevention that considers individual variability in genes, environment, and lifestyle. It discusses key concepts such as genetics, genomics, genetic variation, and applications in oncology and pharmacogenomics. The document also outlines several national initiatives focused on precision medicine like the Precision Medicine Initiative and research networks such as eMERGE. Examples of precision medicine implementation in clinical practice and research are also summarized.
UCSF Informatics Day 2014 - Keith R. Yamamoto, "Precision Medicine"CTSI at UCSF
Keith R. Yamamoto, PhD — Opening Remarks – Precision Medicine
Vice Chancellor for Research
Executive Vice Dean of the School of Medicine
Professor of Cellular and Molecular Pharmacology
UCSF
This document summarizes a presentation on new sources of big data for precision medicine. It discusses how new data sources like genomics, the human microbiome, epigenomics, and the exposome are generating large amounts of data. It then covers the evolution of precision medicine from concepts like personalized medicine and how strategic initiatives in the UK and US are supporting precision medicine research through funding programs and projects like the Cancer Genome Atlas, eMERGE, and exposome studies. The presentation raises the question of whether we are ready for precision medicine given these new data sources and research efforts.
The document summarizes Dr. Matthieu-P. Schapranow's presentation at the Festival of Genomics in Boston on turning big medical data into precision medicine. It describes an in-memory database approach that enables real-time analysis of heterogeneous medical data sources. This allows clinicians and researchers to interactively explore patient data, clinical trials, pathways, and literature to obtain personalized treatment recommendations. The system was designed using a human-centered methodology to ensure usability, effectiveness, and feasibility for precision medicine applications.
The reality of moving towards precision medicineElia Stupka
How do we move towards precision medicine? How can we deliver on the big data in health promise? Who will be the enablers and players? Pharma, Big Tech, or newcomers?
This document discusses the challenges and issues surrounding the implementation of precision medicine in clinical practice. It outlines several challenges, including the lack of manpower of geneticists and genetic counselors, difficulty integrating genetic testing and results into clinical workflows, determining which genetic results are actionable, prioritizing testing, educating physicians and patients, and technical challenges involving laboratories, electronic health records, and developing clinical decision support tools. It also discusses some of the ethical, legal and social issues, such as potential genetic discrimination, handling variants of unknown significance, returning results to patients and family members, privacy and consent for use of genetic data, and the modification of human genomes.
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...Dexter Hadley
Lecture Objectives:
1) To use examples from my research to define and introduce the ideals of precision medicine and digital health. 2) To introduce how large scale population-wide analysis of data can be used to facilitate these two ideals. 3) To introduce how freely available open data can be used to facilitate these two ideals. 4) To show how mobile technology can be used to facilitate these two ideals.
This document outlines a presentation on digital medicine and new challenges for health informatics. It discusses how digital technologies are converging with medicine and impacting patients through wearables, apps, direct-to-consumer services, and social networks. Precision medicine and participatory health are highlighted as key research areas. The role of biomedical informatics is examined in relation to social media, self-quantification, and exposome informatics. Research being conducted at HaBIC and potential frameworks for understanding quantified self data and its therapeutic benefits are summarized.
UCSF Informatics Day 2014 - Keith R. Yamamoto, "Precision Medicine"CTSI at UCSF
Keith R. Yamamoto, PhD — Opening Remarks – Precision Medicine
Vice Chancellor for Research
Executive Vice Dean of the School of Medicine
Professor of Cellular and Molecular Pharmacology
UCSF
This document summarizes a presentation on new sources of big data for precision medicine. It discusses how new data sources like genomics, the human microbiome, epigenomics, and the exposome are generating large amounts of data. It then covers the evolution of precision medicine from concepts like personalized medicine and how strategic initiatives in the UK and US are supporting precision medicine research through funding programs and projects like the Cancer Genome Atlas, eMERGE, and exposome studies. The presentation raises the question of whether we are ready for precision medicine given these new data sources and research efforts.
The document summarizes Dr. Matthieu-P. Schapranow's presentation at the Festival of Genomics in Boston on turning big medical data into precision medicine. It describes an in-memory database approach that enables real-time analysis of heterogeneous medical data sources. This allows clinicians and researchers to interactively explore patient data, clinical trials, pathways, and literature to obtain personalized treatment recommendations. The system was designed using a human-centered methodology to ensure usability, effectiveness, and feasibility for precision medicine applications.
The reality of moving towards precision medicineElia Stupka
How do we move towards precision medicine? How can we deliver on the big data in health promise? Who will be the enablers and players? Pharma, Big Tech, or newcomers?
This document discusses the challenges and issues surrounding the implementation of precision medicine in clinical practice. It outlines several challenges, including the lack of manpower of geneticists and genetic counselors, difficulty integrating genetic testing and results into clinical workflows, determining which genetic results are actionable, prioritizing testing, educating physicians and patients, and technical challenges involving laboratories, electronic health records, and developing clinical decision support tools. It also discusses some of the ethical, legal and social issues, such as potential genetic discrimination, handling variants of unknown significance, returning results to patients and family members, privacy and consent for use of genetic data, and the modification of human genomes.
From Bits to Bedside: Translating Big Data into Precision Medicine and Digita...Dexter Hadley
Lecture Objectives:
1) To use examples from my research to define and introduce the ideals of precision medicine and digital health. 2) To introduce how large scale population-wide analysis of data can be used to facilitate these two ideals. 3) To introduce how freely available open data can be used to facilitate these two ideals. 4) To show how mobile technology can be used to facilitate these two ideals.
This document outlines a presentation on digital medicine and new challenges for health informatics. It discusses how digital technologies are converging with medicine and impacting patients through wearables, apps, direct-to-consumer services, and social networks. Precision medicine and participatory health are highlighted as key research areas. The role of biomedical informatics is examined in relation to social media, self-quantification, and exposome informatics. Research being conducted at HaBIC and potential frameworks for understanding quantified self data and its therapeutic benefits are summarized.
Precision Medicine is now a funded NIH initiative and an organic movement in the clinic and at the research institute. Based on work with Genomics England, multiple large pharmaceutical firms, and research hospitals, attendees will learn about the best practices for epidemiology, signal detection, research, and the clinical diagnostics associated with Precision Medicine, including the development of high-scale bio-repositories that link traditional patient data with genomic information. Come hear about how leadership, collaboration, consent, and compute can lead to success or failure in your Precision Medicine initiative, and how to bring your stakeholders together for an aligned mission response.
Chapter 15 precision medicine in oncologyNilesh Kucha
This document discusses precision medicine in oncology and molecular monitoring of cancer patients. It describes how molecular characterization of tumors can guide treatment decisions and help develop targeted therapies. Next-generation DNA sequencing is allowing large amounts of tumor DNA to be analyzed to identify molecular targets and guide clinical trials matching treatments to tumor mutations. Challenges include limiting sequencing to known targets, accounting for germline variants, incidental findings, and integrating sequencing results into clinical decision making. Repeated biopsies during treatment can provide insights into drug sensitivity and resistance mechanisms in individual patients.
This document outlines a public health approach for realizing the promises of genomics and big data while addressing the challenges. It recommends: 1) Using a strong epidemiological foundation to study disease distribution and determinants in populations. 2) Developing a robust knowledge integration process to synthesize findings from different sources and disciplines. 3) Applying principles of evidence-based medicine and population screening to evaluate genomic applications. 4) Developing a robust translational research agenda beyond clinical applications to improve population health impact. The public health framework can help maximize the benefits of genomics and big data while minimizing risks.
The document discusses opportunities for improving healthcare through precision medicine and integrating genomic and quantified self data. It identifies several pain points in the current healthcare system such as inefficient appointments and a lack of preventative care. Interviews with patients and providers revealed that neither group fully understands genetic data and they desire more participation. The aim is to present a vision for how genomic data could influence health services through opportunities like providing actionable steps based on genetic counseling, combining family history with genomic data, and enabling preventative health measures from a young age.
2015 09-14 Precision Medicine 2015, London, Alain van GoolAlain van Gool
Outline of my view hoe personalized health(care) is more than just targeted medicines, also including personal motivation and actions towards disease prevention. It also outlines 4 key factors that should be in order for optimal personalized health(care): 1. start with patients first, 2. Accelerate translation research to application, 3. Copy best practice, 4. Spread the word.
Acs finding promiscuous old drugs for new uses-finalSean Ekins
The document discusses finding new uses for existing drugs through repurposing or repositioning old drugs. It notes that repurposing drugs can be more cost-effective than developing new drugs and can help address neglected and rare diseases. The document analyzes datasets of drugs identified in in vitro screens to have new biological activities and orphan drugs approved for rare diseases. It finds that drugs identified in screens tend to be more hydrophobic and higher weight than orphan drugs. It advocates for developing better curated databases of drug structures and properties to enable in silico screening for new uses. Overall, the document makes the case that repurposing existing drugs is a promising strategy to develop new treatments, especially for rare and neglected diseases, and that informatics
Precision Medicine: Opportunities and Challenges for Clinical TrialsMedpace
The momentum and muscle behind "finding the right drug for the right patient at the right dose" has further escalated with President Barack Obama’s announcement of a $215 million dollar Precision Medicine Initiative earlier this year. In this webinar, Dr. Frank Smith will explore advances in precision medicine and how it is affecting clinical research. As a pediatric hematologist/oncologist, he will use his extensive clinical and research background as a backdrop for the discussion.
Topics will include:
The evolution of "personalized medicine" to "precision medicine"
How state-of-the-art molecular biology is creating new diagnostic and prognostic strategies
How these new strategies are helping inform the design of clinical trials
Case study: How precision medicine is improving clinical trials in hematology and oncology
Jihad Obeid is an Associate Professor of Public Health Sciences at the Medical University of South Carolina (MUSC). He received his BS in Biology from the American University of Beirut and his MD from the same institution. He completed residency training in pediatrics at Duke University Medical Center and fellowships in pediatric endocrinology at Cornell University Medical College and medical informatics at Harvard-MIT. As Co-Director of the Biomedical Informatics Center at MUSC, he oversees several informatics initiatives and leads multiple projects funded by Clinical and Translational Science Awards. His research focuses on informed consent, research permissions management systems, and using electronic health records to support research recruitment. He has over 30
Competition genomic medicine presentationResearchsio
Prepared By Roman Sharkar and Mir Tasfiq Alam. Both of them are students of the B.Pharm Program in Bangladesh. They prepared this ppt file from their choice of interest which is Genomic Medicine. Hope this will handly to the others who are interested in this topic !!
This document discusses using data from the Veterans Affairs (VA) healthcare system to conduct precision oncology research. It describes extracting data from the VA Corporate Data Warehouse, including clinical records from cancer registries and records of patients who received tumor sequencing and immunotherapy. The author builds a cohort of 330 non-small cell lung cancer patients who received immunotherapy before 2018 and had their cancer verified in the registry to study outcomes like the impact of PD-L1 expression on response to treatment. Challenges include lag times in cancer registry reporting and building a large enough cohort to draw powerful conclusions from retrospective analyses.
This study developed and tested a brief self-administered questionnaire called the Complementary and Alternative Management for Asthma (CAM-A) instrument to identify negative beliefs about inhaled corticosteroids (ICS) and endorsement of complementary and alternative medicine (CAM) among urban minority adults with asthma. Psychometric testing identified 17 items representing ICS beliefs and CAM endorsement that demonstrated acceptable reliability. High rates of CAM endorsement, negative ICS beliefs, and uncontrolled asthma were found. CAM endorsement was significantly associated with uncontrolled asthma. Qualitative analysis provided preliminary evidence that use of the CAM-A instrument in primary care visits prompted providers to discuss ICS beliefs and CAM endorsement with patients.
This document discusses precision medicine and its future applications. It notes that currently many patients do not respond to initial treatments for common conditions like depression, asthma, diabetes and Alzheimer's. Precision medicine aims to change this by using massive datasets including genomics, clinical information, and population data to better understand disease at the individual level and tailor diagnosis and treatment specifically for each patient. This more personalized approach could help get the right treatment to patients more quickly and effectively.
Genetics is becoming more personalized with direct-to-consumer genetic testing services like 23andMe. 23andMe analyzes customers' DNA samples and provides information about their ancestry, traits, and disease risks through an online platform. This empowers individuals and facilitates research by creating a large participant network. While challenges remain in fully engaging all stakeholders, personalized genetics has the potential to transform healthcare by better targeting treatment to individual genetics.
Frontiers of Predictive Oncology and ComputingWarren Kibbe
This document discusses the frontiers of computing and predictive oncology. It provides background on the speaker and changes in computing and oncology driven by improved technology and data availability. Cancer is now defined more by underlying molecular characteristics than anatomy. Team science and open data are critical to build predictive models from large datasets and present analysis and results in a timely, human-friendly way to support treatment decisions. Key challenges include improving interoperability, validating algorithms, scaling infrastructure for large data, and reducing cognitive load in data presentation to aid decision making.
Bryan Soper has extensive experience in pharmaceutical competitive intelligence, medical writing, and data analysis. He currently performs contract work analyzing clinical trials and assessing drug approval likelihoods for Genentech. Previously he has analyzed cancer models and clinical trials to identify correlations. He holds a PhD in Molecular Biology from Cornell University and has worked as a postdoctoral scholar at UCSF investigating drug targets.
This document summarizes a presentation on genes and environment in personalized medicine. It discusses:
1) How existing databases of gene-disease associations are limited for applying genome sequencing results to an individual patient due to incomplete data.
2) A database called VARIMED that aims to address these limitations by curating over 12,000 papers and 192,000 SNPs and their associations with 4,400 diseases and phenotypes.
3) Challenges in moving from odds ratios to likelihood ratios for assessing disease risk based on genomic data and an individual's clinical information.
This document provides a summary and review of notable publications in translational bioinformatics from approximately 2014 to early 2015. It begins with an introduction and overview of the goals and process for selecting publications. Several key topics and publications are then highlighted, including precision medicine and clinical prediction models, variation analysis, cancer genomics, clinical applications of genomics, pharmacogenomics, systems biology approaches, and natural language processing. The document concludes with thanks and acknowledges limitations in scope.
From Digitally Enabled Genomic Medicineto Personalized HealthcareLarry Smarr
The document discusses the future of personalized healthcare through digital health technologies and genomic medicine. It describes how continuous monitoring of various biological sensors can capture temporal data on factors like physical activity, diet, sleep, environmental exposures and more. This comprehensive data combined with clinical records, genetic information, and microbial metagenomic analysis can enable true preventative medicine through early detection, feedback loops, and tuning of lifestyle and medical factors.
Dr. Dennis Wang discusses possible ways to enable ML methods to be more powerful for discovery and to reduce ambiguity within translational medicine, allowing data-informed decision-making to deliver the next generation of diagnostics and therapeutics to patients quicker, at lowered costs, and at scale.
The talk by Dr. Dennis Wang was followed by a panel discussion with Mr. Albert Wang, M. Eng., Head, IT Business Partner, Translational Research & Technologies, Bristol-Myers Squibb.
Emerging collaboration models for academic medical centers _ our place in the...Rick Silva
- The document discusses emerging collaboration models between academic medical centers and other organizations in the genomics and precision medicine field, as genomic sequencing capabilities advance and more clinical cases are needed to power artificial intelligence platforms. It explores new partnership approaches around data sharing, patient engagement, infrastructure needs, and how academic medical centers can position themselves in this evolving ecosystem.
Precision Medicine is now a funded NIH initiative and an organic movement in the clinic and at the research institute. Based on work with Genomics England, multiple large pharmaceutical firms, and research hospitals, attendees will learn about the best practices for epidemiology, signal detection, research, and the clinical diagnostics associated with Precision Medicine, including the development of high-scale bio-repositories that link traditional patient data with genomic information. Come hear about how leadership, collaboration, consent, and compute can lead to success or failure in your Precision Medicine initiative, and how to bring your stakeholders together for an aligned mission response.
Chapter 15 precision medicine in oncologyNilesh Kucha
This document discusses precision medicine in oncology and molecular monitoring of cancer patients. It describes how molecular characterization of tumors can guide treatment decisions and help develop targeted therapies. Next-generation DNA sequencing is allowing large amounts of tumor DNA to be analyzed to identify molecular targets and guide clinical trials matching treatments to tumor mutations. Challenges include limiting sequencing to known targets, accounting for germline variants, incidental findings, and integrating sequencing results into clinical decision making. Repeated biopsies during treatment can provide insights into drug sensitivity and resistance mechanisms in individual patients.
This document outlines a public health approach for realizing the promises of genomics and big data while addressing the challenges. It recommends: 1) Using a strong epidemiological foundation to study disease distribution and determinants in populations. 2) Developing a robust knowledge integration process to synthesize findings from different sources and disciplines. 3) Applying principles of evidence-based medicine and population screening to evaluate genomic applications. 4) Developing a robust translational research agenda beyond clinical applications to improve population health impact. The public health framework can help maximize the benefits of genomics and big data while minimizing risks.
The document discusses opportunities for improving healthcare through precision medicine and integrating genomic and quantified self data. It identifies several pain points in the current healthcare system such as inefficient appointments and a lack of preventative care. Interviews with patients and providers revealed that neither group fully understands genetic data and they desire more participation. The aim is to present a vision for how genomic data could influence health services through opportunities like providing actionable steps based on genetic counseling, combining family history with genomic data, and enabling preventative health measures from a young age.
2015 09-14 Precision Medicine 2015, London, Alain van GoolAlain van Gool
Outline of my view hoe personalized health(care) is more than just targeted medicines, also including personal motivation and actions towards disease prevention. It also outlines 4 key factors that should be in order for optimal personalized health(care): 1. start with patients first, 2. Accelerate translation research to application, 3. Copy best practice, 4. Spread the word.
Acs finding promiscuous old drugs for new uses-finalSean Ekins
The document discusses finding new uses for existing drugs through repurposing or repositioning old drugs. It notes that repurposing drugs can be more cost-effective than developing new drugs and can help address neglected and rare diseases. The document analyzes datasets of drugs identified in in vitro screens to have new biological activities and orphan drugs approved for rare diseases. It finds that drugs identified in screens tend to be more hydrophobic and higher weight than orphan drugs. It advocates for developing better curated databases of drug structures and properties to enable in silico screening for new uses. Overall, the document makes the case that repurposing existing drugs is a promising strategy to develop new treatments, especially for rare and neglected diseases, and that informatics
Precision Medicine: Opportunities and Challenges for Clinical TrialsMedpace
The momentum and muscle behind "finding the right drug for the right patient at the right dose" has further escalated with President Barack Obama’s announcement of a $215 million dollar Precision Medicine Initiative earlier this year. In this webinar, Dr. Frank Smith will explore advances in precision medicine and how it is affecting clinical research. As a pediatric hematologist/oncologist, he will use his extensive clinical and research background as a backdrop for the discussion.
Topics will include:
The evolution of "personalized medicine" to "precision medicine"
How state-of-the-art molecular biology is creating new diagnostic and prognostic strategies
How these new strategies are helping inform the design of clinical trials
Case study: How precision medicine is improving clinical trials in hematology and oncology
Jihad Obeid is an Associate Professor of Public Health Sciences at the Medical University of South Carolina (MUSC). He received his BS in Biology from the American University of Beirut and his MD from the same institution. He completed residency training in pediatrics at Duke University Medical Center and fellowships in pediatric endocrinology at Cornell University Medical College and medical informatics at Harvard-MIT. As Co-Director of the Biomedical Informatics Center at MUSC, he oversees several informatics initiatives and leads multiple projects funded by Clinical and Translational Science Awards. His research focuses on informed consent, research permissions management systems, and using electronic health records to support research recruitment. He has over 30
Competition genomic medicine presentationResearchsio
Prepared By Roman Sharkar and Mir Tasfiq Alam. Both of them are students of the B.Pharm Program in Bangladesh. They prepared this ppt file from their choice of interest which is Genomic Medicine. Hope this will handly to the others who are interested in this topic !!
This document discusses using data from the Veterans Affairs (VA) healthcare system to conduct precision oncology research. It describes extracting data from the VA Corporate Data Warehouse, including clinical records from cancer registries and records of patients who received tumor sequencing and immunotherapy. The author builds a cohort of 330 non-small cell lung cancer patients who received immunotherapy before 2018 and had their cancer verified in the registry to study outcomes like the impact of PD-L1 expression on response to treatment. Challenges include lag times in cancer registry reporting and building a large enough cohort to draw powerful conclusions from retrospective analyses.
This study developed and tested a brief self-administered questionnaire called the Complementary and Alternative Management for Asthma (CAM-A) instrument to identify negative beliefs about inhaled corticosteroids (ICS) and endorsement of complementary and alternative medicine (CAM) among urban minority adults with asthma. Psychometric testing identified 17 items representing ICS beliefs and CAM endorsement that demonstrated acceptable reliability. High rates of CAM endorsement, negative ICS beliefs, and uncontrolled asthma were found. CAM endorsement was significantly associated with uncontrolled asthma. Qualitative analysis provided preliminary evidence that use of the CAM-A instrument in primary care visits prompted providers to discuss ICS beliefs and CAM endorsement with patients.
This document discusses precision medicine and its future applications. It notes that currently many patients do not respond to initial treatments for common conditions like depression, asthma, diabetes and Alzheimer's. Precision medicine aims to change this by using massive datasets including genomics, clinical information, and population data to better understand disease at the individual level and tailor diagnosis and treatment specifically for each patient. This more personalized approach could help get the right treatment to patients more quickly and effectively.
Genetics is becoming more personalized with direct-to-consumer genetic testing services like 23andMe. 23andMe analyzes customers' DNA samples and provides information about their ancestry, traits, and disease risks through an online platform. This empowers individuals and facilitates research by creating a large participant network. While challenges remain in fully engaging all stakeholders, personalized genetics has the potential to transform healthcare by better targeting treatment to individual genetics.
Frontiers of Predictive Oncology and ComputingWarren Kibbe
This document discusses the frontiers of computing and predictive oncology. It provides background on the speaker and changes in computing and oncology driven by improved technology and data availability. Cancer is now defined more by underlying molecular characteristics than anatomy. Team science and open data are critical to build predictive models from large datasets and present analysis and results in a timely, human-friendly way to support treatment decisions. Key challenges include improving interoperability, validating algorithms, scaling infrastructure for large data, and reducing cognitive load in data presentation to aid decision making.
Bryan Soper has extensive experience in pharmaceutical competitive intelligence, medical writing, and data analysis. He currently performs contract work analyzing clinical trials and assessing drug approval likelihoods for Genentech. Previously he has analyzed cancer models and clinical trials to identify correlations. He holds a PhD in Molecular Biology from Cornell University and has worked as a postdoctoral scholar at UCSF investigating drug targets.
This document summarizes a presentation on genes and environment in personalized medicine. It discusses:
1) How existing databases of gene-disease associations are limited for applying genome sequencing results to an individual patient due to incomplete data.
2) A database called VARIMED that aims to address these limitations by curating over 12,000 papers and 192,000 SNPs and their associations with 4,400 diseases and phenotypes.
3) Challenges in moving from odds ratios to likelihood ratios for assessing disease risk based on genomic data and an individual's clinical information.
This document provides a summary and review of notable publications in translational bioinformatics from approximately 2014 to early 2015. It begins with an introduction and overview of the goals and process for selecting publications. Several key topics and publications are then highlighted, including precision medicine and clinical prediction models, variation analysis, cancer genomics, clinical applications of genomics, pharmacogenomics, systems biology approaches, and natural language processing. The document concludes with thanks and acknowledges limitations in scope.
From Digitally Enabled Genomic Medicineto Personalized HealthcareLarry Smarr
The document discusses the future of personalized healthcare through digital health technologies and genomic medicine. It describes how continuous monitoring of various biological sensors can capture temporal data on factors like physical activity, diet, sleep, environmental exposures and more. This comprehensive data combined with clinical records, genetic information, and microbial metagenomic analysis can enable true preventative medicine through early detection, feedback loops, and tuning of lifestyle and medical factors.
Dr. Dennis Wang discusses possible ways to enable ML methods to be more powerful for discovery and to reduce ambiguity within translational medicine, allowing data-informed decision-making to deliver the next generation of diagnostics and therapeutics to patients quicker, at lowered costs, and at scale.
The talk by Dr. Dennis Wang was followed by a panel discussion with Mr. Albert Wang, M. Eng., Head, IT Business Partner, Translational Research & Technologies, Bristol-Myers Squibb.
Emerging collaboration models for academic medical centers _ our place in the...Rick Silva
- The document discusses emerging collaboration models between academic medical centers and other organizations in the genomics and precision medicine field, as genomic sequencing capabilities advance and more clinical cases are needed to power artificial intelligence platforms. It explores new partnership approaches around data sharing, patient engagement, infrastructure needs, and how academic medical centers can position themselves in this evolving ecosystem.
Day 2 Big Data panel at the NIH BD2K All Hands 2016 meetingWarren Kibbe
Big data in oncology and implications for open data, open science, rapid innovation, data reuse, reproducibility and data sharing. Cancer Moonshot, Precisions Medicine Initiative (PMI), the Genomic Data Commons, NCI Cloud Pilots, NCI-DOE Pilots, and the Cancer Research Data Ecosystem.
MseqDR consortium: a grass-roots effort to establish a global resource aimed ...Human Variome Project
The success of whole exome sequencing (WES) for highly heterogeneous disorders, such as mitochondrial disease, is limited by substantial technical and bioinformatics challenges to correctly identify and prioritize the extensive number of sequence variants present in each patient. The likelihood of success can be greatly improved if a large cohort of patient data is assembled in which sequence variants can be systematically analysed, annotated, and interpreted relative to known phenotype. This effort has engaged and united more than 100 international mitochondrial clinicians, researchers, and bioinformaticians in the Mitochondrial Disease Sequence Data Resource (MSeqDR) consortium that formed in June 2012 to identify and prioritize the specific WES data analysis needs of the global mitochondrial disease community. Through regular web-based meetings, we have familiarized ourselves with existing strengths and gaps facing integration of MSeqDR with public resources, as well as the major practical, technical, and ethical challenges that must be overcome to create a sustainable data resource. We have now moved forward toward our common goal by establishing a central data resource (http://mseqdr.org/) that has both public access and secure web-based features that allow the coherent compilation, organization, annotation, and analysis of WES and mtDNA genome data sets generated in both clinical- and research-based settings of suspected mitochondrial disease patients. The most important aims of the MSeqDR consortium are summarized in the MSeqDR portal within the Consortium overview sections. Consortium participants are organized in 3 working groups that include (1) Technology and Bioinformatics; (2) Phenotyping, databasing, IRB concerns and access; and (3) Mitochondrial DNA specific concerns. The online MSeqDR resource is organized into discrete sections to facilitate data deposition and common reannotation, data visualization, data set mining, and access management. With the support of the United Mitochondrial Disease Foundation (UMDF) and the NINDS/NICHD U54 supported North American Mitochondrial Disease Consortium (NAMDC), the MSeqDR prototype has been built. Current major components include common data upload and reannotation using a novel HBCR based annotation tool that has also been made publicly available through the website, MSeqDR GBrowse that allows ready visualization of all public and MSeqDR specific data including labspecific aggregate data visualization tracks, MSeqDR-LSDB instance of nearly 1250 mitochondrial disease and mitochodnrial localized genes that is based on the Locus Specific Database model, exome data set mining in individuals or families using the GEM.app tool, and Account & Access Management. Within MSeqDR GBrowse it is now possible to explore data derived from MitoMap, HmtDB, ClinVar, UCSC-NumtS, ENCODE, 1000 genomes, and many other resources that bioinformaticians recruited to the project are organizing.
This document discusses a project called EQUIP that aims to develop new methods for analyzing and displaying qualitative data in patient-centered outcomes research (PCOR). The project will draw on existing studies involving over 200 cancer patients to develop tools for extracting narratives from illness experiences. An "ethnoarray" approach is proposed to visually array patients' narratives based on domains like treatment decisions and social support. The goals are to engage stakeholders like researchers, providers, and patients to establish standards for using qualitative data in PCOR and assess new methods' feasibility in clinical practice. Challenges include bridging different disciplinary approaches, but the project sees opportunities to innovate at the intersection of qualitative and quantitative health research methods.
This document summarizes a panel discussion on transforming patient-generated health data for wellness and biomedical research. The panelists were Susan Peterson, Katherine Kim, Fernando Martin-Sanchez, Cagatay Demiralp, and Pei-Yun Sabrina Hsueh (moderator). Peterson discussed using sensors and mobile apps to monitor cancer patients undergoing radiation therapy to detect early signs of dehydration. Kim discussed leveraging patient data for personalized care coordination. Martin-Sanchez discussed generating evidence from patient data to inform research. Demiralp discussed visualization of patient data. Overall the panel explored opportunities and barriers to using patient-generated data from behavioral sensing to clinical decision support.
This document discusses integrated health monitoring and precision medicine. It defines precision medicine as using big data, clinical, molecular, environmental, and behavioral information to understand disease and improve prevention and treatment outcomes for patients. Integrated health monitoring combines data from various sources like personal health records, sensors, genomics, and environmental exposures to develop a dynamic model of a patient's health over time. Health informatics plays a key role in building systems to integrate these diverse data sources and enable precision medicine approaches.
Translational Genomics towards Personalized medicine - Medhavi Vashisth.pptMedhavi27
This document discusses various approaches to personalized and precision medicine, including stratified medicine, personalized medicine, and precision medicine. It also discusses the role of biomarkers, pharmacogenomics, genetic testing, biobanking, and examples of individualized cancer treatments. Key points include the use of targeted medicines based on disease stage or individual information, and ensuring best outcomes while reducing side effects. The goal of precision medicine is to integrate genomic data to guide health and disease prevention.
With recent advances in Healthcare, Personalized medicine has become a buzzword. The customization of health care, based on DNA sequencing, patient's environmental information, can lead to more efficient treatments.
By integrating various sources of data, personalized medicine improves all aspects of healthcare from prevention to monitoring.
Using the Biomedical Library & Its Resources: Public Health & EpidemiologyUSA Biomedical Library
This document discusses resources available at the Biomedical Library for students and medical professionals. It outlines several library sites that support different medical disciplines and specialties. It also discusses strategies and tools for practicing evidence-based medicine, such as searching medical literature and using synthesized sources to integrate the best research evidence with clinical expertise. Keeping up with new medical information is challenging due to the large volume of publications, and the document recommends several databases and resources that can help users efficiently find relevant information.
A Vision for a Cancer Research Knowledge SystemWarren Kibbe
The document discusses a vision for a cancer research knowledge system that utilizes data commons and cloud platforms. It describes how data commons co-locate data, storage, computing and tools to create interoperable resources for researchers. The Genomic Data Commons aims to make over 30,000 cancer cases FAIR (Findable, Accessible, Interoperable, Reusable) and provide attribution. This will help identify rare cancer drivers and factors influencing therapy response. The system incorporates multiple data types from studies and clinical trials to enable precision medicine approaches.
Data-driven drug discovery for rare diseases - Tales from the trenches (CINF ...Frederik van den Broek
Slides from my talk at the ACS CINF Symposium on Collaborations & Data Sharing in Rare & Orphan Disease Drug Discovery on 31 March 2019 in Orlando.
Abstract:
For the pharmaceutical industry as a whole, addressing the challenge of rare or orphan diseases is high on the agenda. But for the patients and their families, rare diseases can be very isolating and it can often feel like the potential for new treatments is low. One avenue for potential treatments is to identify drug repurposing candidates for the rare disease in question. This talk will give an overview of various collaborative projects undertaken in the last few years, which involved the combination, normalisation and analysis of data from various disparate sources, including some valuable lessons learnt along the way.
Data sharing drivers in precision oncology, biomedical research, and healthcare. Accelerating discovery, innovation, providing credit for all stakeholders - patients, researchers, care providers, payers.
This document summarizes PCORI's efforts to engage patients in research and tool development. It discusses PCORI's priorities in comparative clinical effectiveness research and shared decision making. Examples are provided of pilot projects developing tools like a digital portal for multiple sclerosis patients and integrating patient-reported outcomes into arthritis care. PCORI's vision for a National Patient-Centered Clinical Research Network is outlined, with plans to fund Clinical Data Research Networks and Patient-Powered Research Networks through cooperative agreements.
The document provides an overview of the University of California Health's data analytics platform which combines healthcare data from the six University of California medical centers. It includes details on the health data warehouse such as the total number of patients, types of data collected, and tools used. The platform aims to enable researchers across UC to conduct studies using the large collection of standardized clinical data.
This document summarizes evidence-informed health care for rare diseases. It discusses:
1) Progress in rare disease research including increasing genetic tests available and approved orphan drugs. Clinical interventions and systems of care are important.
2) Why studying systems of care is important to reduce the "effectiveness gap" between clinical trials and real-world outcomes. Translational research from efficacy to effectiveness and population impact is needed.
3) Challenges in studying rare disease care including limited knowledge, defining meaningful outcomes, and study feasibility with small patient numbers. International collaboration is key.
This document discusses using large datasets for population-based health research. It describes how data comes from primary sources like national surveys and disease registries, as well as secondary sources from hospitals, government agencies, and private organizations. Secondary data can be used to monitor trends, study health disparities and geographic variation, and evaluate specific diseases and treatments. While large datasets allow researchers to study rare conditions and draw conclusions about large populations, there are limitations like data quality, lack of clinical details, and generalizability issues that require solutions. Future directions include developing more comprehensive health data networks.
Similar to Patient Centered Care | Unit 8a Lecture (20)
Culture of healthcare_ week 1_ lecture_slidesCMDLMS
This lecture provides an overview of the culture of health care. It defines key terms like health, disease, illness, and health care. It explains that culture refers to integrated patterns of human behavior within groups, and defines the culture of health care. The lecture outlines several themes in the literature on the culture of health care, including patient and workforce diversity and various professional cultures. It emphasizes that health care involves a complex mix of cultures that are not always apparent from within.
Unhappy customers can significantly impact a company's bottom line through negative word-of-mouth advertising and lost sales. Studies show that 68% of unhappy customers felt disinterested or indifferent, and one dissatisfied luxury car owner can cost a dealership $100 million in annual revenue from lost sales. As social media has made it easier for customers to share negative opinions, companies place high value on resolving issues with challenging customers to maintain satisfaction and minimize financial losses.
This document discusses key principles for effective communication between support agents and customers. It emphasizes that listening is an active skill that takes effort. Both parties must be actively involved in the interaction to ensure understanding and progress towards resolution. Trust in the relationship allows for open communication, while mutual alignment of goals establishes shared expectations for resolving issues.
The document lists several challenges that were addressed and initiatives that were implemented including stopping upselling, establishing a quality control team, enforcing support tickets, creating organizational structures, identifying talent, delegating responsibilities, developing KPIs, creating autonomous customer service units, implementing various tools like WalkMe and Izenda, conducting HIPAA awareness sessions, creating a client retention unit, using Power BI for reporting, conducting in-house marketing, and creating CRs for CureX. It also shows the results of a survey on recognition, feedback, suggestions, happiness, satisfaction, wellness, ambassadorship, relationships with managers, relationships with colleagues, and company alignment for the Operations team at CureMD.
This lecture discusses how health information technology can help facilitate error reporting and analysis to improve patient safety. It presents three key HIT mechanisms: automated surveillance systems, online event reporting systems, and predictive analytics/data modeling. The lecture also emphasizes the importance of a culture of safety that encourages open discussion and learning from mistakes without blame. Error reports are analyzed using a risk assessment model to distinguish near misses from events that cause patient harm.
This document discusses quality improvement tools for analyzing health information technology (HIT) errors, including root cause analysis (RCA), failure mode and effects analysis (FMEA), and hazard analysis. RCA is a structured problem-solving process that considers all potential causal factors of an incident. FMEA prospectively predicts error modes by assessing the likelihood and impact of process failures. The document provides examples of using RCA and FMEA to analyze HIT-related errors and identifies key areas of focus for HIT safety measures.
This lecture discusses learning from mistakes and errors in health information technology (HIT). It covers types of errors like slips, mistakes, active failures and latent conditions. It also examines unintended consequences of HIT like new or more work, workflow issues, overdependence on technology, and copy-paste errors. The objectives are to assess HIT for negative consequences and examine common HIT design deficiencies. References from AHRQ and other sources on error reporting and analysis in HIT are also provided.
This document discusses electronic clinical quality measures (eCQMs) which are designed to leverage health information technology (HIT) to improve quality measurement. eCQMs use standardized data elements and terminology to measure care quality based on information in electronic health records. Effective eCQM reporting requires structured, coded data and use of standards for measure specification, calculation, and reporting. Widespread use of eCQMs could revolutionize quality measurement by facilitating automated reporting and improving data quality.
This lecture discusses key attributes of data quality including consistency, currency, timeliness, granularity, precision, and relevancy. It provides examples of each attribute and recommendations for maintaining data integrity such as establishing data governance and defining standards for data collection. The lecture also notes that data quality is important for research and quality improvement efforts and that poor data quality can lead to errors.
This lecture discusses assessing data quality and identifies 10 key attributes of data quality: definition, accuracy, accessibility, comprehensiveness, consistency, currency, timeliness, granularity, precision, and relevancy. Poor data quality can threaten patient safety and quality of care, reduce effectiveness of decision making, and increase costs. The lecture provides examples and recommendations for ensuring each of the 10 data quality attributes.
This lecture discusses assessing data quality and improving it through health information technology (HIT). It identifies common causes of insufficient data quality, such as unclear definitions, incomplete data, and programming errors. Both systematic and random issues can negatively impact data quality. The lecture outlines best practices for preventing, detecting, and improving data quality issues. Standardizing terminology, structuring data entry, and utilizing technologies like voice recognition can enhance data quality. Overall, high quality clinical data is important for healthcare decisions, and HIT professionals can implement strategies to enhance data quality.
This document discusses strategies for implementing health information technology (HIT) systems. It compares "big bang" implementations, where a system is launched system-wide at once, to "staggered" or phased implementations. While big bang implementations have faster rollout, they carry higher risk. Staggered implementations have lower risk but slower return on investment. The document also emphasizes the importance of user training and long-term support during and after implementation to ensure success. Contextual factors like organizational culture and individual user needs must also be considered in planning. Nested implementation teams and designated super-users or internal consultants can help provide support.
The document discusses effective health IT implementation planning. It outlines characteristics of effective implementation teams, including communication, understanding roles, and practical expertise. Three key strategies for health IT implementation are reviewed: single vendor, best of breed, and best of suite. Clinical workflows and the needs of different care settings like primary care and critical access hospitals are also addressed. The goal is to assist organizations in designing customized implementation plans that meet their unique quality and safety needs.
This document discusses a lecture on how health information technology (HIT) can impact patient safety culture. The lecture covers strategies for adaptive work that can be useful for HIT initiatives, including being unwavering in goals while inviting others to help achieve them, addressing real and perceived losses from changes, and assuming healthcare providers want to help patients. References are provided for images and content used in the lecture.
This document discusses health information technology (HIT) and its impact on patient safety culture. It provides learning objectives on adaptive leadership, frameworks for patient safety culture, and differentiating technical and adaptive change. It also summarizes a 2013 medical error case study where a patient received a 39-fold overdose due to a 50-step error-prone process. Root causes of use errors with HIT are identified, such as patient identification errors and data accuracy errors. Frameworks for risk assessment and classifying human interaction with HIT systems are presented. The document concludes that HIT has potential to reduce errors but also introduce new opportunities for errors and overreliance on technology.
This document is a lecture on how health information technology (HIT) can impact patient safety culture. It discusses applying quality improvement tools to analyze HIT errors. It highlights the success of efforts led by Dr. Peter Pronovost to reduce central line bloodstream infections through standardization, independent checks, and learning from defects. Checklists, data collection, and adopting practices from high-reliability industries like aviation and Toyota have helped significantly reduce infection rates.
This document provides an overview of quality improvement methods and tools. It describes several common quality improvement models including the API model, Baldrige criteria, FOCUS-PDCA, PDSA cycle, ISO 9000, Kaizen, Lean thinking, and Six Sigma DMAIC. A variety of basic quality improvement tools are also outlined, such as flowcharts, cause-and-effect diagrams, control charts, Pareto charts, and checklists. Finally, potential mistakes in quality improvement initiatives are reviewed, including choosing an inappropriate topic, lack of defined roles/expectations, and failure to sustain improvements.
This document provides an overview of quality improvement methods for healthcare settings. It describes strategies for quality improvement, including the role of leadership in creating a culture that supports quality improvement. The document discusses concepts like the PDSA cycle and foundations of quality improvement developed by thinkers like Shewhart, Deming, and Juran. The goal is to introduce methods that can be used to identify and redesign processes, collect and analyze data, and make improvements to eliminate problems and strategically change healthcare systems over time.
- Alerts and reminders have the potential to improve patient safety but can also cause clinician frustration and "alert fatigue" if too many are nuisance alerts that provide little benefit.
- Successful alerts are specific, sensitive, clear, concise and support clinical workflow, allowing for safe, efficient responses. They include drug and lab alerts, practice and administrative reminders.
- Research found that drug interaction alerts, disease-drug contraindication alerts and dosing guidelines improved prescribing behaviors while unnecessary lab test repeats dropped with test result reminders.
- Clinical decision support (CDS) aims to improve healthcare decisions and outcomes by providing clinicians with relevant patient information and clinical knowledge. However, CDS has not been widely adopted by clinicians.
- Effective CDS provides the right information to the right person in the right format through the right channels at the right time. It can take many forms, including alerts, order sets, and guidelines.
- CDS helps with administrative tasks, managing clinical complexity, controlling costs, and supporting clinical decision-making. However, poor design can also lead to unintended consequences like alert fatigue.
Digital Health in India_Health Informatics Trained Manpower _DrDevTaneja_15.0...DrDevTaneja1
Digital India will need a big trained army of Health Informatics educated & trained manpower in India.
Presently, generalist IT manpower does most of the work in the healthcare industry in India. Academic Health Informatics education is not readily available at school & health university level or IT education institutions in India.
We look into the evolution of health informatics and its applications in the healthcare industry.
HIMMS TIGER resources are available to assist Health Informatics education.
Indian Health universities, IT Education institutions, and the healthcare industry must proactively collaborate to start health informatics courses on a big scale. An advocacy push from various stakeholders is also needed for this goal.
Health informatics has huge employment potential and provides a big business opportunity for the healthcare industry. A big pool of trained health informatics manpower can lead to product & service innovations on a global scale in India.
This particular slides consist of- what is hypotension,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is the summary of hypotension:
Hypotension, or low blood pressure, is when the pressure of blood circulating in the body is lower than normal or expected. It's only a problem if it negatively impacts the body and causes symptoms. Normal blood pressure is usually between 90/60 mmHg and 120/80 mmHg, but pressures below 90/60 are generally considered hypotensive.
Fit to Fly PCR Covid Testing at our Clinic Near YouNX Healthcare
A Fit-to-Fly PCR Test is a crucial service for travelers needing to meet the entry requirements of various countries or airlines. This test involves a polymerase chain reaction (PCR) test for COVID-19, which is considered the gold standard for detecting active infections. At our travel clinic in Leeds, we offer fast and reliable Fit to Fly PCR testing, providing you with an official certificate verifying your negative COVID-19 status. Our process is designed for convenience and accuracy, with quick turnaround times to ensure you receive your results and certificate in time for your departure. Trust our professional and experienced medical team to help you travel safely and compliantly, giving you peace of mind for your journey.www.nxhealthcare.co.uk
English Drug and Alcohol Commissioners June 2024.pptxMatSouthwell1
Presentation made by Mat Southwell to the Harm Reduction Working Group of the English Drug and Alcohol Commissioners. Discuss stimulants, OAMT, NSP coverage and community-led approach to DCRs. Focussing on active drug user perspectives and interests
This particular slides consist of- what is Pneumothorax,what are it's causes and it's effect on body, risk factors, symptoms,complications, diagnosis and role of physiotherapy in it.
This slide is very helpful for physiotherapy students and also for other medical and healthcare students.
Here is a summary of Pneumothorax:
Pneumothorax, also known as a collapsed lung, is a condition that occurs when air leaks into the space between the lung and chest wall. This air buildup puts pressure on the lung, preventing it from expanding fully when you breathe. A pneumothorax can cause a complete or partial collapse of the lung.
VEDANTA AIR AMBULANCE SERVICES IN REWA AT A COST-EFFECTIVE PRICE.pdfVedanta A
Air Ambulance Services In Rewa works in close coordination with ground-based emergency services, including local Emergency Medical Services, fire departments, and law enforcement agencies.
More@: https://tinyurl.com/2shrryhx
More@: https://tinyurl.com/5n8h3wp8
Mental Health and well-being Presentation. Exploring innovative approaches and strategies for enhancing mental well-being. Discover cutting-edge research, effective strategies, and practical methods for fostering mental well-being.
Satisfying Spa Massage Experience at Just 99 AED - Malayali Kerala Spa AjmanMalayali Kerala Spa Ajman
Our Spa Massage Center Ajman prioritizes efficiency to ensure a satisfying massage experience for our clients at Malayali Kerala Spa Ajman. We offer a hassle-free appointment system, effective health issue identification, and precise massage techniques.
Our Spa in Ajman stands out for its effectiveness in enhancing wellness. Our therapists focus on treating the root cause of issues, providing tailored treatments for each client. We take pride in offering the most satisfying Pakistani Spa service, adjusting treatment plans based on client feedback.
For the most result-oriented Russian Spa treatment in Ajman, visit our Massage Center. Our Russian therapists are skilled in various techniques to address health concerns. Our body-to-body massage is efficient due to individualized care and high-grade massage oils.
CHAPTER 1 SEMESTER V COMMUNICATION TECHNIQUES FOR CHILDREN.pdfSachin Sharma
Here are some key objectives of communication with children:
Build Trust and Security:
Establish a safe and supportive environment where children feel comfortable expressing themselves.
Encourage Expression:
Enable children to articulate their thoughts, feelings, and experiences.
Promote Emotional Understanding:
Help children identify and understand their own emotions and the emotions of others.
Enhance Listening Skills:
Develop children’s ability to listen attentively and respond appropriately.
Foster Positive Relationships:
Strengthen the bond between children and caregivers, peers, and other adults.
Support Learning and Development:
Aid cognitive and language development through engaging and meaningful conversations.
Teach Social Skills:
Encourage polite, respectful, and empathetic interactions with others.
Resolve Conflicts:
Provide tools and guidance for children to handle disagreements constructively.
Encourage Independence:
Support children in making decisions and solving problems on their own.
Provide Reassurance and Comfort:
Offer comfort and understanding during times of distress or uncertainty.
Reinforce Positive Behavior:
Acknowledge and encourage positive actions and behaviors.
Guide and Educate:
Offer clear instructions and explanations to help children understand expectations and learn new concepts.
By focusing on these objectives, communication with children can be both effective and nurturing, supporting their overall growth and well-being.
At Malayali Kerala Spa Ajman we providing the top quality massage services for our customers.
Our massage center prioritizes efficiency to ensure a quality massage experience for our clients at Malayali Kerala Spa Ajman. We offer a convenient appointment system and precise massage services.
Reach us at Villa No 7, Near Ammar Bin Yasir Street Al Rashidiya 2 - Ajman - United Arab Emirates.
Phone : +971 529818279
Health Tech Market Intelligence Prelim Questions -Gokul Rangarajan
The Ultimate Guide to Setting up Market Research in Health Tech part -1
How to effectively start market research in the health tech industry by defining objectives, crafting problem statements, selecting methods, identifying data collection sources, and setting clear timelines. This guide covers all the preliminary steps needed to lay a strong foundation for your research.
This lays foundation of scoping research project what are the
Before embarking on a research project, especially one aimed at scoping and defining parameters like the one described for health tech IT, several crucial considerations should be addressed. Here’s a comprehensive guide covering key aspects to ensure a well-structured and successful research initiative:
1. Define Research Objectives and Scope
Clear Objectives: Define specific goals such as understanding market needs, identifying new opportunities, assessing risks, or refining pricing strategies.
Scope Definition: Clearly outline the boundaries of the research in terms of geographical focus, target demographics (e.g., age, socio-economic status), and industry sectors (e.g., healthcare IT).
3. Review Existing Literature and Resources
Literature Review: Conduct a thorough review of existing research, market reports, and relevant literature to build foundational knowledge.
Gap Analysis: Identify gaps in existing knowledge or areas where further exploration is needed.
4. Select Research Methodology and Tools
Methodological Approach: Choose appropriate research methods such as surveys, interviews, focus groups, or data analytics.
Tools and Resources: Select tools like Google Forms for surveys, analytics platforms (e.g., SimilarWeb, Statista), and expert consultations.
5. Ethical Considerations and Compliance
Ethical Approval: Ensure compliance with ethical guidelines for research involving human subjects.
Data Privacy: Implement measures to protect participant confidentiality and adhere to data protection regulations (e.g., GDPR, HIPAA).
6. Budget and Resource Allocation
Resource Planning: Allocate resources including time, budget, and personnel required for each phase of the research.
Contingency Planning: Anticipate and plan for unforeseen challenges or adjustments to the research plan.
7. Develop Research Instruments
Survey Design: Create well-structured surveys using tools like Google Forms to gather quantitative data.
Interview and Focus Group Guides: Prepare detailed scripts and discussion points for qualitative data collection.
8. Sampling Strategy
Sampling Design: Define the sampling frame, size, and method (e.g., random sampling, stratified sampling) to ensure representation of target demographics.
Participant Recruitment: Plan recruitment strategies to reach and engage the intended participant groups effectively.
9. Data Collection and Analysis Plan
Data Collection: Implement methods for data gathering, ensuring consistency and validity.
Analysis Techniques: Decide on analytical approaches (e.g., statistical
Test bank clinical nursing skills a concept based approach 4e pearson educati...rightmanforbloodline
Test bank clinical nursing skills a concept based approach 4e pearson education
Test bank clinical nursing skills a concept based approach 4e pearson education
Test bank clinical nursing skills a concept based approach 4e pearson education
Test bank clinical nursing skills a concept based approach 4e pearson educati...
Patient Centered Care | Unit 8a Lecture
1. Patient-Centered Care
Precision Medicine
Lecture a
This material (Comp 25 Unit 8) was developed by the University of Alabama at Birmingham, funded by the
Department of Health and Human Services, Office of the National Coordinator for Health Information
Technology under Award Number 90WT0007.
This work is licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International
License. To view a copy of this license, visit http://creativecommons.org.
2. Precision Medicine
Learning Objectives
• Define precision medicine and key concepts associated
with it
• Describe the major current applications in the practice of
precision medicine
• Discuss national initiatives including the NIH Precision
Medicine Initiative
• Describe the activities of national research networks
focused on precision medicine
3. What is Precision Medicine?
• Precision Medicine
– “an emerging approach for disease treatment
and prevention that takes into account
individual variability in genes, environment,
and lifestyle for each person.”
• Personalized Medicine
• P4 Medicine
– predictive, personalized, preventive,
participatory
Source: (NIH, 2016, The Precision Medicine Initiative
Hood and Friend, 2011.)
4. Key Concepts
• Genetics: study of individual genes and role in
hereditary traits
• Genomics: study of all genetic material and
relationship with environment
• Genetic variation:
– SNPs (single nucleotide polymorphisms)
– INDEL (insertion / deletion)
• GWAS
– Scan of SNPs association with single phenotype
– Linking genomic variants with disease
Source (The Jackson Laboratory, 2016)
5. Key Concepts 2
• Genotype and Phenotype
• PheWAS
– Scan of phenotypes to determine association
with single gene variant
• Germline and somatic mutations
• Other “-omics”
– Proteomics
– Metabolomics
Source: (Denny et al 2010)
6. Key Concepts 3
• Exposome
– Individual exposures
o Environmental
o Internal
• Precision Medicine
– Genomics
– Other –omics
– Environment
– Lifestyle
Source: (Martin-Sanchez et al, 2014)
7. Analysis of Genetic Data
• Family Trees
• GWAS
• PheWAS
• Candidate gene association studies
8. Applications in Practice
• Pharmacogenomics
– Predict response to medications
– Tailored drug selection
– Adjust dosages
Source: (Denny, Wylie, Peterson, 2016)
9. Applications in Practice 2
• Oncology
– Diagnosis
– Therapy
– Prognosis
• Gene-disease associations
– Increased knowledge due to research on
germline testing
10. National Initiatives
• Precision Medicine Initiative
– National research cohort of >1 million people
• Research Networks
– eMERGE
– PGRN
– PCORnet
– IGNITE
Source: (Precision medicine cohort initiative, 2015; eMERGE network, 2014; PGRN 2016;
Pcornet, 2015; NIH, 2016)
11. eMERGE Network
• Electronic Medical Records and Genomics
• Integration of genomic data into the EHR
• Using the EHR to identify phenotypes
• Developing clinical decision support
• Integrating knowledge resources into EHR
Source: (Gottesman, et al. 2013)
12. Pharmacogenomics Research
Network (PGRN)
• Research on response to medications based on
genomics
• Research on tailoring medications to individuals
• Collaboration with eMERGE Network
Source: (Pharmacogenomics Research Network, 2016)
13. PCORnet
• Patient Centered Clinical Research Network
– Clinical Data Research Networks (CDRNs)
– Patient Powered Research Networks
(PPRNs)
• Funded by the Patient Centered Outcomes
Research Institute (PCORI)
Source: (Collins et al. 2014)
14. IGNITE
• Implementing GeNomics In PracTicE
• Funded by the NIH National Human Genome
Research Institute
• Demonstration projects
• Exploration of strategies to implement genomics
in clinical care
Source: (NIH, 2016)
15. Discovery Efforts in Precision
Medicine
• Geisinger
– Rural Pennsylvania
– Large data repository for quality improvement
and research
– Biorepository with over 45,000 individuals
– Opt-in genomic testing
Source: (Wade et al, 2014)
16. Discovery Efforts in Precision
Medicine 2
• Vanderbilt
– Biorepository (BioVU)
o Originally ‘Opt-out’
– Over 200,000 de-identified samples
– Transitioning to ‘Opt-in’ consent process
– Researchers use de-identified and identified
samples
Source: (Denny, Wylie, Peterson, 2016)
17. Implementation in Practice
• Pre-emptive vs reactive testing
– Test in advance and have data available
o Provide clinical decision support when needed
– Test when patient actually has disease
Source: (Denny, Wylie, Peterson, 2016)
18. Precision Medicine
Summary – lecture a
• Basic definitions
• National initiatives
• Examples of use of precision medicine in
clinical practice and research
19. Precision Medicine
References – lecture a
References
Collins, F. S., Hudson, K. L., Briggs, J. P., & Lauer, M. S. (2014). PCORnet: turning a dream into
reality. Journal of the American Medical Informatics Association : JAMIA, 21(4), 576–577.
www.ncbi.nlm.nih.gov
Denny, J. C., Ritchie, M. D., Basford, M. A., Pulley, J. M., Bastarache, L., Brown-Gentry, K., &
Crawford, D. C. (2010). PheWAS: demonstrating the feasibility of a pheonme-wide scan to
discover gene-disease associations. Bioinformatics, 26(9), 1205-1210. www.ncbi.nlm.nih.gov
Denny, J. C., Wiley, L. K., & Peterson, J. F. (2016). Use of Clinical Decision Support to Tailor Drug
Therapy Based on Genomics. In E. S. Berner, Clinical Decision Support Systems (Third ed.).
Springer. Forthcoming.
Gottesman, O., Kuivaniemi, H., Tromp, G., Faucett, W. A., Li, R., Manolio, T. A., … and The eMERGE
Network. (2013). The Electronic Medical Records and Genomics (eMERGE) Network: past,
present, and future. Genetics in Medicine, 15(10), 761–771. www.ncbi.nlm.nih.gov
Hood, L., & Friend, S. H. (2011). Predictive, personalized, preventive, participatory (P4) cancer
medicine. Nat Rev Clin Oncol, 8(3), 184-7. www.nature.com
The Jackson Laboratory. (2016). The Difference Between Genetics and Genomics. Retrieved April 27,
2016, from The Jackson Laboratory: www.jax.org
Martin Sanchez, F., Gray, K., Bellazzi, R., Lopez-Campos, G., & Martin Sanchez, F. (2014, May).
Exposome informatics: considerations for the design of future biomedical research information
systems. J Am Med Inform Assoc, 21(3), 386-390. www.ncbi.nlm.nih.gov
19
20. Precision Medicine
References 2 – lecture a
References
National Human Genome Research Institute. (2014). eMERGE NETWORK - Electronic Medical
Records and Genomics. Retrieved April 26, 2016, from eMERGE NETWORK:
emerge.mc.vanderbilt.edu
National Institutes of Health. (2016). IGNITE - Implementing GeNomics In PracTicE. Retrieved April
27, 2016, from Implementing GeNomics In PracTicE (IGNITE) Network: www.ignite-genomics.org
National Institutes of Health. (n.d.). Precision Medicine Initiative Cohort Program. Retrieved April 27,
2016, from Precision Medicine Initiative: www.nih.gov
Pharmacogenomics Research Network. (2016, April 26). Retrieved from PGRN: http://www.pgrn.org/
The National Patient-Centered Clinical Research Network. (2015). pcornet. Retrieved April 26, 2016,
from The National Patient-Centered Clinical Research Network: pcornet.org
Wade, J. E., Ledbetter, D. H., & Williams, M. S. (2014, March). Implementation of genomic medicine in
a health care delivery system: a value proposition? Am J Med Genet C Semin Med Genet, 112-6.
onlinelibrary.wiley.com
20
21. Patient-Centered Care
Precision Medicine
lecture a
This material was developed by the
University of Alabama at Birmingham,
funded by the Department of Health and
Human Services, Office of the National
Coordinator for Health Information
Technology under Award Number
90WT0007.
21
Editor's Notes
Welcome to Patient Centered Care, Precision Medicine. This is lecture A.
Patient-centered care is broadly considered as attending to the unique values and needs of the individual patient, communicating about diagnosis and treatment in a way that the patient can understand, and engaging and involving patients in their own care. The idea behind precision medicine is that a patient’s care should be crafted based on the unique characteristics of each patient—their genetics, their environment and their lifestyle. Aspects of precision medicine are just beginning to be implemented in a few places, but are likely to exponentially expand over the coming years. While precise definitions vary, precision medicine involves incorporating the use of biological and environmental data into clinical care to make both diagnosis and treatment more precise and effective. While there are many types of ‘-omics’ (pronounced OH-micks) data, genomics is closest to broad adoption or translation into clinical practice and will be the focus of this unit. This lecture will examine the basic concepts and some of the current initiatives in precision medicine.
The objectives for this unit, Precision Medicine, are to:
Define precision medicine and key concepts associated with it;
Describe the major current applications in the practice of precision medicine;
Discuss national initiatives including the NIH Precision Medicine Initiative; and
Describe the activities of national research networks focused on precision medicine.
According to NIH, precision Medicine is “an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person.” It is called precision medicine because the assumption is with this additional information, we can be more precise about risks of disease or benefits of treatments for a given individual and can design treatments that are better tailored to the unique genetic, environmental, and lifestyle makeup of the individual. As an example, we have known for a long time that the anticoagulant clopidogrel (pronounced clo-PID-uh-grel), or Plavix, works for most patients, but not all. If we know that an individual has a gene that decreases clopidogrel’s effectiveness, we can develop a different treatment plan immediately, rather than waiting to see how the individual responds to the standard drug regimen. Not only is this less risky for the patient, it is likely to save costs as well.
Although precision medicine is a relatively new term, older similar terms that are still used are personalized medicine and what has been called P4 medicine. P4 stands for “predictive, personalized, preventive, participatory”, a term coined by Leroy Hood.
According to the Jackson Laboratory, which is an institution that breeds mice with certain characteristics so they can be used for research on diseases , Genetics “is the study of heredity, or how characteristics of living organisms are transmitted from one generation to the next.” Jackson Laboratory defines genomics as the “study of the entirety of an organisms’ genes—called the genome.” Research in genetics involves known genes, and often single genes known to cause a specific disease; genomic research often involves discovery of new associations, frequently of multiple genes by looking at whole genomes of individuals with or without some complex diseases. Scientists look for variants in what are called SNPs (pronounced snips) between these two groups. These genome-wide association studies, or GWAS (pronounced G-wass) discover associations that can form the basis for hypotheses for further genomic research.
The genotype of an individual describes the specific genes in their body that were inherited from their parents. The phenotype describes an individual’s physical or clinical characteristics. PheWAS (pronounced fee-wass) are phenome-wide association studies, that scan the clinical record to determine phenotypes associated with a single gene variant. While the genotype remains stable over the course of a person’s life, there can be changes in individual cells of the body that are called mutations. If these mutations occur in the sperm or egg cells, they are called germline mutations and can be passed on to offspring. If they occur in other cells of the body, such as when cancer develops, they are known as somatic mutations.
In addition to genomics, there are other –omics (pronounced OH-micks) that refer to “the studies of the roles, relationships and actions of the various types of molecules that make up the cells of an organism.” Examples include proteomics (pronounced Pro-T-omics) the study of proteins, and metabolomics (pronounced met-TAB-o-lomics), the study of cellular metabolism.
Another concept that has not yet become very widespread is the idea of the “exposome” (pronounced expo-zome). The exposome refers to a detailed description, quantified if possible, of all of an individual’s exposures, both environmental and internal. Precision medicine will ultimately involve both genomic, other omics, as well as environmental and lifestyle data, but to date, most of the focus has been on genomic data and that is the focus of this presentation as well.
For many years we have incorporated genetic data into clinical care by collecting data on family trees and using that data to identify genetic diseases. With genome-wide association studies we have generated many hypotheses to test specific associations of a variety of genes with specific clinical conditions. Conversely, with the increased availability of clinical data in electronic form we have moved to PheWAS studies, looking at phenotypes associated with specific gene variants. Finally, in using these data we can identify candidate genes for specific association studies. These studies are adding to our knowledge that bring us closer to widespread application to clinical care.
While geneticists and genetic counselors use a variety of genomic analyses in their work, there are two areas where genomics has already found its way beyond the researchers and genetic specialists into other areas of clinical practice.
One of these areas is pharmacogenomics (pronounced FARM-uh-co-GEN-o-micks) which uses genomic data to make prescribing more precise. The example we gave earlier of clopidogrel prescribing is an example of using genomics to predict responses to medication and select the most appropriate medication. Other uses have been to assist with dosing, where genomics is used to identify individuals who have increased or decreased sensitivity to a given medication. Warfarin dosing informed by genomic testing can prevent dangerous side effects of this potent medication.
Oncology is another area that has made use of genomic data for more precise diagnosis of the type of cancer and more precise therapy. In addition to genetic testing to determine if a patient has mutations in a specific gene such as BRCA 1 or 2 (pronounced B-R-C-A) that would increase the risk of breast cancer, analysis of the genome of the cancer tumor itself can provide information on sensitivities of the tumor to various types of treatments. For oncology, prognosis is also highly altered by tumor gene molecular subtypes. For example, if a patient has what is known as “triple-negative breast cancer” there is no target for therapy.
The type of testing involved in the oncology applications is somatic testing that examines characteristics of the tumor cell, but the research on germline testing has led to more knowledge about gene-disease associations.
There are several national initiatives that promise to dramatically increase the knowledge we will have for incorporating precision medicine into clinical practice. NIH’s Precision Medicine initiative that was announced by President Obama in the 2015 State of the Union address involves increasing NIH funding to build a “national research cohort of one million or more Americans” who will provide both genomic and clinical data for research. This cohort will cover a broad range of diseases, in fact, NIH says “all diseases.” There is additional funding specifically targeting precision medicine in oncology.
This new effort and funding will supplement some existing research networks that themselves have developed large cohorts of patients. Three networks that have been ongoing include the eMERGE (pronounced emerge) Network, the Pharmacogenomics Research Network or PGRN (pronounced P-G-R-N), and PCORnet (pronounced P-Core-net).
The NIH-funded eMERGE Network as of the end of 2015 consists of nine institutions. EMERGE stands for “Electronic Medical Records and Genomics.” Each of the 9 institutions obtains both clinical and genomic data from individuals, but they also use the electronic health record to identify phenotypes for different diseases. They have a library of phenotypes that others with EHRs can use. Current foci (pronounced foe-sigh) for eMERGE are integrating genomic data into the EHR and integrating clinical decision support and knowledge resources for precision medicine into the EHR.
The Pharmacogenomics Research network or PGRN does research on identifying how individuals respond to medication based on their genetic characteristics and studies the impact of tailoring medications to an individual’s unique genetic make-up. They have collaborated with the EMERGE network on studying several medications including warfarin and clopidogrel.
PCORnet consists of two types of research networks, although both of them are collecting both clinical and genomic data on individuals. The CDRNs (pronounced C-D-R-Ns) are building the infrastructure to extract data from EHRs for research. Each CDRN consists of multiple institutions who will be conducting research using the data in their EHR systems.
The second type of network is the PPRN. Each PPRN (pronounced P-P-R-N) is engaging patients with a particular disease to contribute data for research. The PPRNs are particularly interested in comparative effectiveness research related to their disease. The two networks obviously can work together with the PPRN enriching what is already the EHRs that can be shared over the PCORnet infrastructure.
Another research network is the IGNITE consortium. Ignite stands for implementing genomics in practice, an acronym that is a bit of a reach but does sound better than IGNIP or IGIP. The aim of the consortium, which involves six academic institutions, some of which are also eMERGE or PGRN sites, is to conduct demonstration projects and study strategies for effective implementation and sustainability.
These national initiatives will greatly increase the evidence base for precision medicine, but they will do more than that. The engagement of large numbers of people in research that supports precision medicine will also educate them and make it easier to translate this research into practice. The use of precision medicine in practice, however, has already begun.
As an example, several large healthcare systems have made precision medicine a priority. Both Geisinger (pronounced Guy-singer) Health System and Vanderbilt University are part of the eMERGE Network, but their work to build genomic repositories predated their participation in the eMERGE Network. Geisinger, a large integrated delivery system in rural Pennsylvania has had an electronic health record since 1995 that includes a data repository for research and quality improvement. They started a biorepository in 2007 and have consented over 45,000 individuals. Individuals have to opt in to have their data included in the biorepository.
Until recently, Vanderbilt had one of the few opt-out biorepositories. When patients signed the consent for care forms, they were told that leftover blood or other tissue samples may be used for research, including genomic research. Patients could opt out of having their samples in the data repository, but few did. Vanderbilt’s repository has over 200,000 unique individuals, but they have now transitioned to an opt-in model like Geisinger’s. Vanderbilt’s basic biorepository, called BioVU (pronounced bio-view) is de-identified, but some projects have used identified data as well.
Both Geisinger and Vanderbilt have incorporated genomic data into their Electronic Health Records by using what is known as pre-emptive genetic testing. That is, they test the patient’s blood samples for known disease associated genetic variants, such as those that lead to decreased sensitivity to clopidogrel, and then provide clinical decision support so that the information is available to physicians when they have a patient for whom they would ordinarily prescribe clopidogrel. The alternative to pre-emptive testing is reactive testing, which is testing done only when the patient has a condition that needs the test. There is debate over which approach is best.
This concludes Precision Medicine, Lecture a.
In summary, we have defined some of the basic concepts that underlie the new model of person-centered care known as precision medicine. We discussed national initiatives and gave examples of its use in clinical practice and research, including pharmacogenomics and cancer care.